FDA Opening the Door on CRLs. What It Means for Biotech.

Something unusual is happening at the FDA.

According to BioCentury, the agency is actively exploring paths forward for companies that recently received Complete Response Letters. Biohaven, Regenxbio, and Sydnexis have all held meetings with FDA's chief counsel following high-profile regulatory setbacks. That's not normal. CRLs are usually where programs go to die, or at best get delayed for years while sponsors run additional trials.

The timing matters. Vinay Prasad just resigned as director of the Center for Biologics Evaluation and Research and as FDA's chief scientist and chief medical officer. Prasad was the loudest voice against accelerated approval based on surrogate endpoints. He wanted more stringent efficacy standards across the board. His exit removes the biggest internal obstacle to a more sponsor-friendly regulatory posture.

There's also a coordinated push from patient advocates, members of Congress, and conservative media pressuring the agency to reconsider these decisions. When political pressure and regulatory turnover align, policy shifts follow.

Why this matters for M&A.

A Complete Response Letter doesn't just kill a drug program. It kills the company's value as an acquisition target. No buyer wants to acquire a program the FDA already rejected. But if the FDA starts reversing or softening CRLs, that math changes overnight. Programs that were written off become approvable again. Companies that were trading at cash value suddenly have pipeline value again.

This is broadly bullish for small cap biotech. The companies directly mentioned, Biohaven, Regenxbio, and Sydnexis, are the first movers. But any company sitting on a recent CRL with surrogate endpoint data should be watching this closely.

The regime at FDA is shifting. The door that Prasad closed is opening back up. For M&A hunters, that means names the market left for dead might deserve a second look.

Worth watching.